Bristol Myers Squibb

OPDUALAG

Manufacturer:

Bristol Myers Squibb

Opdualag HCPCS:

J9298

HCPCS Code Descriptor:

Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg

Category:

J Code

Opdualag NDCs:

00003-7125-11

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Opdualag:

OPDUALAG is an Oncology drug manufactured by Bristol Myers Squibb and administered via the Intravenous route of administration. The J Code: J9298 is aligned to the drug OPDUALAG.

Opdualag belongs to the group of drugs known as antineoplastic combinations and is used to treat certain types of cancer. This drug is a combination two different medications known as nivolumab and relatlimab. Opdualag is administered to the patient via intravenous infusion over the course of 30 minutes. Opdualag is a branded drug manufactured by the Bristol-Myers Squibb Company. Patient assistance programs for Opdualag can be found through Bristol-Myers Squibb’s Access Support.

ACCESS PRICING AND MORE BY REGISTERING

J9298 Added Date:

October 1, 2022

J9298 Effective Date:

October 1, 2022

J9298 Termination Date:

HCPCS Active

Opdualag billing and coding information can be found through Bristol Myers Squibb at the link below:
Opdualag patient assistance information can be found through Bristol Myers Squibb Access Support at the URL: https://www.bmsaccesssupport.bmscustomerconnect.com/patient
OPDUALAG prescribing information can be found at the link below:
Information regarding OPDUALAG’s side effects can be found at MedlinePlus